Becker's Healthcare September 23, 2024
Paige Twenter

Amid expectations that the popularity of GLP-1 drugs will decrease bariatric surgery rates, a Cleveland Clinic-led study found these surgeries might be more effective than GLP-1s for some patients.

Cleveland Clinic researchers analyzed chronic kidney disease progression and incident kidney failure data among 425 patients who either underwent metabolic surgery or continuously took GLP-1s for at least two years. All had Type 2 diabetes, obesity and stage 3 or 4 chronic kidney disease.

Compared to GLP-1s, metabolic surgery was associated with a 60% lower risk of kidney disease progression and a 44% lower risk...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Related Articles:
Early hospice care has transformative impact
Study shows growing cancer treatment inequities between high and low-income countries
STAT+: UnitedHealth pays its own physician groups considerably more than others, driving up consumer costs and its profits
California Sets 15% Goal for Primary Care Spending by 2034
AI Robot Scanner as Good as Rheumatologists at Assessing RA

Share This Article